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Design, synthesis and molecular docking of novel triazole 
derivatives as potential CoV helicase inhibitors
Middle East respiratory syndrome coronavirus (MERS-CoV) 
had emerged and spread because of the worldwide travel and 
inefficient healthcare provided for the infected patients in 
several countries. Herein we investigated the anti-MERS-CoV 
activity of newly synthesized sixteen halogenated triazole 
compounds through the inhibition of helicase activity using 
the FRET assay. All new compounds underwent justification 
for their target structures via microanalytical and spectral 
data. SAR studies were performed. Biological results revealed 
that the most potent compounds were 4-(cyclopent-1-en-
-3-ylamino)-5-(2-(4-iodophenyl)hydrazinyl)-4H-1,2,4-triazole-
-3-thiol (16) and 4-(cyclopent-1-en-3-ylamino)-5-[2-(4-chloro-
phenyl)hydrazinyl]-4H-1,2,4-triazole-3-thiol (12). In silico 
molecular docking of the most potent compounds was per-
formed to the active binding site of MERS-CoV helicase 
nsp13. Molecular docking results are in agreement with ex-
perimental findings.
Keywords: triazole derivatives, anti-MERS-CoV activity, 
MERS-CoV helicase, docking
Coronaviruses represent substantial human pathogens that have risen multiple times 
from zoonotic reservoirs over the past few centuries (1). Middle East respiratory syndrome 
coronavirus (MERS-CoV) is a recently discovered coronavirus. It is considered a threat to 
global public health, causing severe pneumonia in patients of the Middle East, with 40 % 
fatality rate (2). It was first isolated in September 2012 (3). Both severe acute respiratory 
syndrome coronavirus (SARS-CoV) and MERS-CoV belong to the Coronaviridae family, 
which are enveloped, are positive-stranded RNA viruses with approximately 30,000 nu-
cleotides (4). MERS-CoV displays symptoms like human severe acute respiratory syn-
drome (SARS) infections, consisting of sickness, rigors, weaknesses and high fevers, signs 
like influenza infection, but later develops to atypical pneumonia in most of the cases and 
commonly fatal acute respiratory illness (5).
The fatality rate in patients infected with MERS-CoV, estimated to be 43 % as reported 
by World Health Organization (WHO), is higher than that of SARS (estimated 15 %) and is 
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strongly age- and sex-dependent (6). Recent transmission in healthcare settings was obvi-
ous due to the contact and use of facilities by non-diagnosed infected patients. It has been 
reported by WHO that the majority, namely 83 % of the cases, were identified in Saudi 
Arabia (7). However, many antiviral agents have been identified to inhibit MERS in vitro, 
though there are currently no approved antiviral agents or vaccines available to tackle any 
potential MERS outbreaks (8). Stockman and co-workers (9) reported that the present anti-
viral agents had minimal beneficial effects and had sometimes even worsened the symp-
toms of SARS patients. There are no specific treatments for MERS, therefore there is a need 
to develop effective anti-SARS agents for any SARS or MERS outbreak in the future. Prog-
ress in the drug development combating MERS is based on different molecular targets, one 
of which is based on coronavirus helicase (10). 
Helicases are proteins that catalyze the separation of duplex oligonucleotides into 
single strands exploiting the derived energy from ATP hydrolysis (11).
The MERS-CoV helicase non-structural protein 13 (M-nsp13) is a critical component 
for viral replication and is presently viewed as a possible drug target for potential corona-
virus chemical inhibitors (12). Its substrates are double-stranded RNAs (dsRNA). The main 
mode of action is the unwinding of a substrate in a process depending mainly on ATP 
gradient in a 5’-to-3’ direction. Length of the 5’ loading strand of the partially duplex RNA 
substrate is another factor playing a crucial role affecting the efficiency of the unwinding 
reaction (13). Because of all these helicase functions, MERS helicase is considered a power-
ful antiviral target.
 Triazoles are versatile heterocyclic moieties with a broad spectrum of pharmacological 
activities (14). He and coworkers (15) reported that triazole derivatives had shown potency 
as antiviral agents against H1N1influenza virus. The 1,2,4-triazole derivative was found to 
show the best activity against influenza B among all of compounds evaluated in a study 
by Zhao and Aisa (16). A limited number of possible inhibitors of nsp13 have been explored 
(17). SSYA10-001 is a 1,2,4-triazole derivative which was reported as an nsp13 non-competitive 
inhibitor through the blockage of SARS and MERS-CoV replication. It was postulated that 
SSYA10-001 binding pocket of SARS-CoV nsp13 is preserved among different coronavirus 
helicases, indicating the discovery of broad-spectrum coronavirus inhibitors. SSYA10-001was 
reported as potential effective inhibitor of viral replication in MERS-CoV replicon (Fig. 1) 
(18).
All the above mentioned prompted us to design and synthesize new 1,2,4-triazole 
derivatives in order to be screened as helicase inhibitors that simply prevent the replication 
of MERS-CoV.
Fig. 1. SSYA10-001 docking into the inhibitor-binding pocket of MERS-CoV (18).
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A Stuart melting point apparatus (Stuart Scientific, UK) was used for the recording of 
uncorrected melting points in open capillary tubes. An FT-IR Shimadzu spectrometer 
(Shimadzu, Japan) was used for recording IR spectra. A Bruker AC-500 Ultra Shield NMR 
spectrometer (Bruker, Switzerland) was used for recording 1H NMR and 13C NMR spectra, 
at 500 MHz. Trimethylsilane was used as an internal standard. Deuterated dimethylsulf-
oxide was the solvent of choice. An HP Model MS-5988 (Hewlett Packard, USA) was used 
for recording mass spectra. A Carlo Erba 1108 Elemental Analyzer (W. C. Heraeus GmbH, 
Germany) was used for providing microanalyses. All elemental analyse values were within 
± 0.4 % of the theoretical value.
Starting triazole and all reagents used were of analytical grade and were purchased 
from Sigma (USA). 
Syntheses
The solvent-free reaction of arylamines constitutes one of the most widely used methods 
for the preparation of different amine derivatives (19).
General procedure for 4-amino-5-(substituted phenyl hydrazine)-4H-1,2,4-triazole-3-thiols 1–8. 
– A mixture of 4-amino-5-hydrazino-4H-1,2,4-triazole-3-thiol (1 g, 0.007 mol) and different 
reagents (0.007 mol) (1,2-difluorobenzene (0.8 g), 1,4-difluorobenzene (0.8 g), 1,2-dichloroben-
zene (1 g), 1,4-dichlorobenzene (1 g), 1,2-dibromobenzene (1.65 g), 1,4-dibromobenzene (1.65 g), 
1,2-diiodobenzene (2.3 g) or 1,4-diiodobenzene (2.3 g) was heated at 150 °C for 5 min with 
stirring. The formed residue was dried and recrystallized from ethanol to give compounds 
1–8, resp.
The obtained compounds were: 4-amino-5-(2-fluorophenyl hydrazine)-4H-1,2,4-triazole-
3-thiol (1), 4-amino-5-(4-fluorophenyl hydrazine)-4H-1,2,4-triazole-3-thiol (2), 4-amino-5-(2-
chlorophenyl hydrazine)-4H-1,2,4-triazole-3-thiol (3), 4-amino-5-(4-chlorophenyl hydra zine)-
4H-1,2,4-triazole-3-thiol (4), 4-amino-5-(2-bromophenyl hydrazine)-4H-1,2,4-triazole-3-thiol 
(5), 4-amino-5-(4-bromophenyl hydrazine)-4H-1,2,4-triazole-3-thiol (6), 4-amino-5-(2-iodophe-
nyl hydrazine)-4H-1,2,4-triazole-3-thiol (7), 4-amino-5-(4-iodophenyl hydrazine)-4H-1,2,4-tri-
azole-3-thiol (8).
General procedure for 4-(cyclopent-1-en-3-ylamino)-5-[2-(substituted phenyl) hydrazinyl]-4H-
1,2,4-triazole-3-thiols 9–16. – Each of compounds 1–8 reacted with an equimolar quantity of 
3-chlorocyclopent-1-ene under fusion at 150 °C for 5 min with stirring. The formed residue 
was dried and recrystallized from ethanol to give compounds 9–16, resp.
The obtained compounds were: 4-(cyclopent-1-en-3-ylamino)-5-[2-(2-fluorophenyl) 
hydrazinyl]-4H-1,2,4-triazole-3-thiol (9), 4-(cyclopent-1-en-3-ylamino)-5-[2-(4-fluorophenyl) 
hydrazinyl]-4H-1,2,4-triazole-3-thiol (10), 4-(cyclopent-1-en-3-ylamino)-5-[2-(2-chlorophenyl)
hydrazinyl]-4H-1,2,4-triazole-3-thiol (11), 4-(cyclopent-1-en-3-ylamino)-5-[2-(4-chlorophenyl 
hydrazinyl]-4H-1,2,4-triazole-3-thiol (12), 4-(cyclopent-1-en-3-ylamino)-5-[2-(2-bromo-
 phenyl)hydrazinyl]-4H-1,2,4-triazole-3-thiol (13), 4-(cyclopent-1-en -3-ylamino)-5-[2-(4- 
- bromophenyl)hydrazinyl]-4H-1,2,4-triazole-3-thiol (14), 4-(cyclopent-1-en-3-ylamino)-5- 
- [2-(2-iodophenyl)hydrazinyl]-4H-1,2,4-triazole-3-thiol (15), 4-(cyclopent-1-en-3-ylamino)- 
-5-[2-(4-iodophenyl)hydrazinyl]-4H-1,2,4-triazole-3-thiol (16).
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Biological investigations
M-nsp13 helicase preparation. – Antiviral activity was tested using a helicase specific 
assay in which a purified M-nsp13 cloned helicase domain was used. GenBank accession 
no. JX869059.2. (Bi Biotech, New Delhi, India). PCR was used for the amplification of the 
DnaB helicase from E. coli genomic, according to the literature procedure (20). PET28a 
conjugated plasmid was used for the expression to which a  purified PCR product was 
translocated to. Conjugated M-nsp13-pET28a was cultivated overnight in LB culture for 
expression. M-nsp13 was obtained by SDS-polyacrylamide gel electrophoresis (PAGE). 
Separated protein was stored at –20 °C to be used in ATPase assay using standard method 
(21), where sonication and centrifugation were carried out to obtain the insoluble fraction. 
Purification was accomplished by washing with 50 mmol L–1 Tris-HCl (pH 7.4). The ob-
tained protein was then dissolved in a mixture of 6 mol L–1 CuCl2, 50 mmol L–1 Tris HCl 
(pH 7.4) and 20 mmol L–1 imidazole. Protein renaturation was done by rapid vortexing of 
the soluble protein into a mixture of Tris HCl (pH 6.8), 5 mmol L–1 MgCl2, 20 % glycerol/1 
% Triton, 10 mmol L–1 β-mercaptoethanol, on ice. The protein was eluted with 100 mmol 
L–1 Tris pH 8.0, 150 mmol L–1 NaCl, 10 mmol L–1 desthiobiotin, 0.1 % Triton X-100, 5 mmol 
L–1 β-mercaptoethanol and 5 % glycerol, then the protein was stored at –20 °C.
ATPase assay. – Measuring the ATPase assay was carried through phosphomolybdate-
-Malachite green assay 5 min reaction. The reaction mixture consisted of 50 mmol L–1 Tris- 
-HCl (pH 6.8), 5 mmol L–1 MgCl2, 0.1 mg mL–1 BSA and 3.2 ng M-nsp13 helicase, in 50 µL.
The newly synthesized derivatives 1–16 were evaluated for their ATPase inhibitory 
activity in different concentrations. Fitting of the data was done by using the modified 
form of the equation first given by Porter (21):
 A([L]) = 1 – {(ΔA∞[L])/(IC50 + [L])}
where A([L]) is the ATPase activity at a ligand concentration [L] (L – MgCl2), and ΔA∞ is the 
maximal decrease in ATPase activity at an infinite concentration of L. IC50 was extrapo-
lated from the curve for each compound tested.
FRET-based helicase assays. – The convenient method reported by Boguszewska and co-
workers (22), was used for testing both helicase and ATPase activity colorimetrically and 
fluorometrically through fluorescence resonance energy transfer (FRET). The amount of 
phosphate released during the reaction is reduced via present ATPase inhibitors and so the 
measured absorbance is reduced. This protocol relies on the cloning of M-nsp 13. Expression 
was done by utilizing the following primer forward: 5′BamHI-nsp13-CGGGATCCTG CTG-
TAGGCTCTTGTGTTG-3′ and 3′EagI-nsp13-ATGCGGCCGCTATTGCAGCTTGTAG TTGG-
TAAAGCTC-3′ as the reverse one. In brief, annealing was done by heating a mixture of the 
two primers at a ratio 1:1.2 of forward:reverse primers to 90 °C, then cooling over one hour to 
40 °C. Newly synthesized derivatives 1–16 were then added to the reaction mixture in vary-
ing concentrations. Released phosphate is quantified after 5 min in the colorimetric assay. To 
mimic the nucleic acid-stimulated NTPase activity of the m-nsp13 helicase, Oligo-dT24 was 
incorporated in the assay. The average change of fluorescence at excitation 550 nm and emis-
sion 570 nm was reported in triplicate, as an indicator of the extent of duplex unwinding. Data 
were fitted using the standard equation and IC50 for each derivative was estimated.
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Molecular modeling. – Docking investigation was carried using the molecular operating 
environment (MOE 2008.10) (23) on the basis of high-resolution crystal structures of MERS-
CoV nsp13 helicase: Protein Data Bank (PDB), 5WWP (Fig. 2). Target protein and compounds, 
synthesized as ligands, were energy-minimized. Removal of water molecules and the addi-
tion of hydrogen atoms were performed. Assignment of amino acid residues’ protonation, 
using the Protonate3D algorithm with 30 total runs was done. Most potent newly synthe-
sized compounds 4-(cyclopent-1-en-3-ylamino)-5- [2-(4-iodophenyl) hydrazinyl]-4H-1,2,4- 
-triazole-3-thiol (16) and 4-(cyclopent-1-en-3-ylamino)-5-[2-(4-chlorophenyl) hydrazinyl]-4H- 
-1,2,4-triazole-3-thiol (12), were docked into MERS-CoV nsp13 helicase site. Interactions with 
amino acid residues were identified within the active binding site.
RESULTS AND DISCUSSION
Chemistry
The starting 4-amino-5-hydrazino-4H-1,2,4-triazole-3-thiol has a highly reactive nu-
cleophilic character with three nucleophilic active centers that promote different substitu-
tion reactions. Sixteen new compounds were obtained in very good to excellent yields and 
screened against MERS CoV-helicase activity. The synthetic pathways adopted for the syn-
thesis of the target 1,2,4-triazole-based compounds 1–16 proceeded via simple, straight 
forward and solvent-free reactions which are outlined in Scheme 1.
In a structure-activity relationship (SAR) discussion, SSYA10-001 was taken as a lead 
compound and main features required for inhibiting MERS-CoV nsp13 (Fig. 1) were ob-
served (Fig. 3).
Fig. 2. Crystal structure of Middle East respiratory syndrome coronavirus helicase (MERS-CoV 
nsp13) (PDB 5WWP).
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Structures of all obtained compounds were verified through IR, 1H NMR, 13C NMR, 
mass spectra and microanalytical data which were in conformity with the allocated struc-
tures (Tables I and II).
IR spectra of compounds 1–8, displayed characteristic bands ascribed to aromatic CH 
groups at 3051–3059 cm–1 confirming the reaction of the starting triazole with phenyl re-
agents. 1H NMR spectra for compounds 1–8 revealed extra multiplet signals at δ 7.30–8.08 
ppm attributed to the introduced phenyl moiety. NH2 moiety was displayed at δ 2.38 ppm. 
NH signals were allocated at δ 4.79–4.83 ppm, exchangeable with D2O, in addition to the 
signal at δ 4.30 ppm allocated for SH group, exchangeable with D2O. 13C NMR spectrum 
of compound 1 revealed signals at δ 114, 116.5, 121, 125, 145 and 155 ppm attributed to in-
troduced ortho-substituted phenyl moiety. para-fluoro compound 2 displayed four signals 
at δ 114, 116, 147 and 150 ppm, attributed to introduced para-substituted phenyl moiety. 
Moreover, mass spectra showed molecular ion peaks with m/z at 240, 258, 303 and 348 [M+] 
for compounds 1–2, 3–4, 5–6 and 7–8, resp.
IR spectra of compounds 9–16, showed disappearance of the double intense peak of 
NH2, confirming a reaction at the specified position. Also, IR spectra showed absorption 
bands at 3053–3059 cm–1 assigned to the introduced aromatic moiety. In addition, appear-
ance of bands in the range 2888–2953 cm–1, allocated for aliphatic hydrocarbons of cyclo-
pentenyl ring, confirmed reaction at the specified position. 1H NMR spectra for target 
compounds 9–16 displayed extra multiplet signals at δ 3.84, 4.24, 4.40, 4.60, 4.80 ppm, attri-
buted to the introduced cyclopentene moiety. Additionally, there were multiplet signals 
at δ 6.90–8.01 ppm ascribed to ortho-substituted phenyl moieties in compounds 9, 11, 13 
and 15. However, compounds 10, 12, 14 and 16 displayed doublet of doublet signals (6.69, 
6.93 ppm), (7.96, 8.12 ppm), (7.64, 7.91 ppm) and (7.96, 8.24 ppm), resp., for four CH2 groups 
of para-substituted phenyl ring. Presence of NH and SH signals was confirmed at specified 
























1, 9 R = 2-F
2, 10 R = 4-F
3, 11 R = 2-Cl
4, 12 R = 4-Cl
150 OC 150 OC
5, 13 R = 2-Br
6, 14 R = 4-Br
7, 15 R = 2-I
8, 16 R = 4-I
Scheme 1
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Table I. Physicochemical and analytical data of the newly synthesized compounds 1–16
Compd. Molecular formula (Mr)
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positions, exchangeable with D2O. 13C NMR spectra for compounds 9–16 also revealed 
additional signals at δ 39.34 and 40.87 ppm attributed to the two carbons of cyclopentenyl. 
C-NH of the cyclopentenyl was seen at δ 61.72 ppm, confirming its reaction at the specified 
position, whereas the C=C of the cyclopentenyl appeared at δ 130.05 and 133.01 ppm. Phenyl 
carbons’ signals were seen at 114.01–154.07 ppm. Mass spectra were consistent with assumed 
structures where molecular ion peaks m/z at 306, 324, 368 and 414 [M+], were seen for com-
pounds 9–10, 11–12, 13–14 and 15–16, resp. (Table II).
Biological activity
Till now there is no approved MERS CoV helicase inhibitors; however, some adamantine- 
-derived bananins were reported as potent inhibitors of SARS CoV helicase with IC50 values 
from 2.7 to more than 100 µmol L–1 (24).
Inhibition of helicase MERS-CoV enzymatic activity. – In this work, we have investigated 
the activity of newly halogenated 1,2,4 triazole derivatives (1–16) against MERS-CoV heli-
case. Current results showed that the starting compound 4-amino-5-hydrazino-4H-1,2,4- 
-triazole-3-thiol inhibited the M-nsp 13 helicase and ATPase activity with IC50 value of 12.4 
and 8.9 µmol L–1, resp. (Table III). We herein showed that some halogenated 1,2,4-triazole 
derivatives revealed significant anti-MERS-CoV activity.
ATPase assays revealed that the presence of cyclopentenyl moiety is essential for good 
activity. Compounds 4-(cyclopent-1-en-3-ylamino)-5-[2-(4-iodophenyl) hydrazinyl]-4H-1,2,4-
triazole-3-thiol (16) and 4-(cyclopent-1-en-3-ylamino)-5- [2-(4-chlorophenyl) hydrazinyl]-4H- 
-1,2,4-triazole-3-thiol (12) were the most effective MERS-CoV helicase inhibitors with ATPase 
IC50 values of 0.47 and 0.51 µmol L–1, resp. ortho-iodo derivative (15) with ATPase IC50 of 2.73 
µmol L–1 and ortho-chloro derivative (11) with ATPase IC50 of 3.9 µmol L–1 were also moderate 
inhibitors. On the other hand, bromine derivatives 14 and 13 showed moderate inhibition 
with ATPase IC50 of 4.0 and 5.3 µmol L–1, resp. Compounds 9 and 10, bearing the fluorine 
atom, showed little if any inhibition, whereas compounds 1–8 showed no inhibition at all 
(Table III). Mostly, the measured helicase activity inhibition for each compound was lower 
than the corresponding ATPase inhibition activity.
Molecular modeling
The major step to initiate drug design is to identify and select the most appropriate drug 
target. The target protein for this study is M-nsp 13 helicase protein (Fig. 2). Docking of the 
most potent compounds, 4-(cyclopent-1-en-3-ylamino)-5-[2-(4-iodophenyl) hydrazinyl]-4H- 
-1,2,4-triazole-3-thiol (16) and 4-(cyclopent-1-en-3-ylamino)-5-[2-(4-chlorophenyl) hydrazinyl]-
-4H-1,2,4-triazole-3-thiol (12), was performed in the active binding site of 5WWP. Thirty 
conformations for each browser molecule were saved. Finally, the best conformation with 
best binding interactions along with the lowest binding energy was selected (Fig. 4).
Binding of compounds in 5WWP active site could be attributed to the incorporation 
of a nitrogen atom and aromatic rings, which is generally common to other inhibitors as 
SSYA-10. However, the difference in their substitution pattern resulted in the difference in 
their binding affinity. Molecular modeling result confirms the crucial role of the following 
amino acids in the active pocket: Tyr 159, Tyr 7, Tyr 171 and Arg 163. It was obvious that 
the binding interaction with Tyr 159 is essential for activity.
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Structure-activity relationship (SAR)
It is clear from the obtained results of the biological evaluation that, in general, the 
existence of cyclopentene in structure of compounds under assay is essential for activity. 
The para-substitution in 4-(cyclopent-1-en-3-ylamino)-5-[2-(halophenyl) hydrazinyl]-4H- 
-1,2,4-triazole-3-thiols 9–16 is better for helicase inhibitory activity. Additionally, the in-
hibitory activity varies according to the halogen-type substitution. It was observed that the 
most potent derivative was that comprising iodine followed by chlorine and then bromine. 
The weakest activity, if any, was noticed with fluoro-derivatives. This comes in accordance 
with the previous studies reporting that iodo-derivatives exhibited the most potent activity 








4-Amino-5-(2-fluorophenyl hydrazine)-4H-1,2,4-triazole-3-thiol (1) > 100 > 100
4-Amino-5-(4-fluorophenyl hydrazine)-4H-1,2,4-triazole-3-thiol (2) > 100 > 100
4-Amino-5-(2-chlorophenyl hydrazine)-4H-1,2,4-triazole-3-thiol (3) > 100 > 100
4-Amino-5-(4-chlorophenyl hydrazine)-4H-1,2,4-triazole-3-thiol (4) 94.81 > 100
4-Amino-5-(2-bromophenyl hydrazine)-4H-1,2,4-triazole-3-thiol (5) > 100 > 100
4-Amino-5-(4-bromophenyl hydrazine)-4H-1,2,4-triazole-3-thiol (6) > 100 > 100
4-Amino-5-(2-iodophenyl hydrazine)-4H-1,2,4-triazole-3-thiol (7) > 100 > 100
4-Amino-5-(4-iodophenyl hydrazine)-4H-1,2,4-triazole-3-thiol (8) 87.64 > 100
4-(Cyclopent-1-en-3-ylamino)-5-[2-(2-fluorophenyl) hydrazinyl]-4H-
1,2,4-triazole-3-thiol (9) > 100 > 100
4-(Cyclopent-1-en-3-ylamino)-5-[2-(4-fluorophenyl) hydrazinyl]-4H-
1,2,4-triazole-3-thiol (10) 58 > 100
4-(Cyclopent-1-en-3-ylamino)-5-[2-(2-chlorophenyl) hydrazinyl]-4H-
1,2,4-triazole-3-thiol (11) 3.9 5.7
4-(Cyclopent-1-en-3-ylamino)-5-[2-(4-chlorophenyl) hydrazinyl]-4H-
1,2,4-triazole-3-thiol (12) 0.51 3.0
4-(Cyclopent-1-en-3-ylamino)-5-[2-(2-bromo-phenyl) hydrazinyl]-4H-
1,2,4-triazole-3-thiol (13) 5.3 9.0
4-(Cyclopent-1-en-3-ylamino)-5-[2-(4-bromo-phenyl) hydrazinyl]-4H-
1,2,4-triazole-3-thiol (14) 4.0 6.3
4-(Cyclopent-1-en-3-ylamino)-5-[2-(2-iodophenyl) hydrazinyl]-4H-
1,2,4-triazole-3-thiol (15) 2.73 4.3
4-(Cyclopent-1-en-3-ylamino)-5-[2-(4-iodophenyl) hydrazinyl]-4H-
1,2,4-triazole-3-thiol (16) 0.47 2.5
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as helicase inhibitors against replication of coronaviruses (24). In addition, it was reported 
that the aromatic substituent influences dramatically te anti-corona viruses activity (25). 
The current study reveals that orientation of halogen affected the activity, so that para- 
-substituted compounds within the series 9–16 were showed higher helicase inhibitory 
activity compared to the ortho-ones.
CONCLUSIONS
Sixteen new halogenated triazole derivatives were designed and synthesized. Struc-
tures of target compounds were justified via microanalytical and spectral data. Obtained 
compounds 1–16 were subjected to evaluation against MERS-CoV helicase. The most 
potent compounds were p-iododerivative, 4-(cyclopent-1-en-3-ylamino)-5-[2-(4-iodophe-
nyl) hydrazinyl]-4H-1,2,4-triazole-3-thiol (16), and para-chloro derivative, 4-(cyclopent-
1-en-3-ylamino)-5-[2-(4-chlorophenyl)hydrazinyl]-4H-1,2,4-triazole-3-thiol (12). In silico, 
molecular docking was accomplished on the most potent compounds into the active 
binding site of MERS-CoV helicase nsp13, to support the experimental findings. Compu-
tational results harmonize well with the experimental ones.
Therefore, exploring new anti-MERS-CoV agents might lead to future drugs after full 
toxicological and preclinical investigations.
Fig. 4. a) 4-(Cyclopent-1-en-3-ylamino)-5-[2-(4-iodophenyl)hydrazinyl]-4H-1,2,4-triazole-3-thiol (16) 
docking into inhibitor binding pocket of MERS-CoV (5WWP), b) 4-(Cyclopent-1-en-3-ylamino)-
5-[2-(4-chlorophenyl)hydrazinyl]-4H-1,2,4-triazole-3-thiol (12) docking into binding pocket of MERS-
CoV (5WWP). c) SSYA-10 docking into inhibitor binding pocket of MERS-CoV (5WWP).
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